Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
The initiative

Prof. Michel Farnier

Prof. Michel Farnier  
Point Medical Clinic
Dijon, France
 
Present position
 
Director of the Lipid Clinic at the Point Medical Clinic in Dijon, France
 
Education and training
 

Michel Farnier graduated from Dijon University, France, in 1974 with a Doctorate in Physical Chemistry and obtained his medical degree in 1981. He later completed a human biology diploma in specialized pharmacology and his specialty training in Endocrinology and Nutrition Disease at the University of Dijon. Michel Farnier has a long history of teaching science and medicine at the University of Burgundy in Dijon.

 
Editorial activity and publications
 

Michel Farnier’s research has resulted in the publication of numerous articles in key journals such as: American Journal of Cardiology, American Heart Journal, Archives of Internal Medicine, Clinical Therapeutics, European Heart Journal, International Journal of Cardiology, Journal of the American College of Cardiology, Journal of Clinical Lipidology, Journal of Lipid Research, Metabolism.

 
Research interests
 

Michel Farnier has contributed significantly to medical research in the areas of dyslipidaemia and type 2 diabetes. His research interests include lipid lowering drugs and the genetics of dyslipidaemia. He was involved in numerous clinical trials in the field of lipid lowering drugs, diabetes and obesity.

 
Scientific publications (since 2000)
 

FARNIER M, PORTAL JJ, MAIGRET P. Efficacy of Atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Therapeut 2000, 5: 27-32.

FARNIER M, DEJAGER S and the French Fluvastatin Study Group. Effect of combined fluvastatin-fenofibrate therapy compared to fenofibrate monotherapy in severe primary hypercholesterolemia. Am J Cardiol 2000; 85: 53-57.

GUERIN M, LASSEL TS, LE GOFF W, FARNIER M, CHAPMAN MJ. Action of atorvastatin in combined hyperlipidemia. Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000; 20: 189-197.

FARNIER M, PICARD S. Synthetic optically pure statins. Investigational Drugs 2000; 3: 897-906.

KREMPF M, ROHMER V, FARNIER M, ISSA-SAYEGH M, CORDA C, SIRUGUE I, GERLINGER C, MASSEYEFF-ELBAZ MF. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia. Diabetes and Metabolism 2000; 26: 184-191.

SAINT-JORE B, VARRET M, DACHET C, RABES JP, DEVILLERS M, ERLICH D, BLANCHARD P, KREMPF M, MATHE D, CHANU B, JACOTOT B, FARNIER M, BONAITI-PELLIE C, JUNIEN C, BOILEAU C. Autosomal dominant type IIa hypercholesterolemia : evaluation of the respective contributions of LDLR and APOB gene defects as well as a third major group of defects. European Journal of Human Genetics 2000; 8: 621-630.

FARNIER M. Quelle place pour une association statine-fibrate dans le traitement des hyperlipidémies ? Le Courrier de l’Arcol 2000; 3: 138-140.

FARNIER M. Association statine et fibrate : pour quels patients et dans quelles conditions ? Diabétologie, Nutrition et Facteurs de Risque 2000; 6: 229-231.

FARNIER M. En prévention des maladies cardiovasculaires : comment dépister et diagnostiquer une dyslipidémie ? Diabétologie, Nutrition et Facteurs de Risque 2000 ; 6 : 259.

FARNIER M, PICARD S. Diabetes : Statins, Fibrates, or Both ? Current Atherosclerosis Reports 2001; 3: 19-28.

FARNIER M. Quid des phytostérols. Diabétologie, Nutrition et Facteurs de Risque 2001; 7: 19-21.

FARNIER M. Que faire quand une hyperlipidémie résiste aux doses usuelles de statines ? Cardiologie Pratique 2001; 561: 14-15.

FARNIER M. Hyperlipidémies du sujet âgé. La Presse Médicale 2001; 30: 957-63.

STEIN EA, FARNIER M, WALDSTREICHER J, MERCURI M, on behalf of the Simvastatin/Atorvastatin Study Group. Effects of statins on biomarkers of bone metabolism: A randomised trial. Nutr Metab Cardiovasc Dis 2001; 11: 84-87.

KREMPF M, FARNIER M. Obésité et risque cardiovasculaire Ann Endocrinol 2001; 62: 1523-1529.

AMOUYEL P, FARNIER M, LYON G, SIEST G, MORTIER N, AMIOT N, DUPRAT-LOMON I. Prise en charge des dyslipidémies diagnostiquées en médecine générale en France - Etude PRAGMA. Arch Mal Cœur 2001; 94: 1045-53.

FARNIER M. A propos des nouvelles recommandations françaises et américaines sur le dépistage et le traitement des hyperlipidémies. Le Courrier de l’Arcol et de la SFA 2002; 4: 32-35.

FARNIER M. Hypercholestérolémie : les adjuvants et les alternatives des statines. Entretiens de Bichat 2002, Médecine Expansion Scientifique Française, p 95-97.

FARNIER M. Ezetimibe in hypercholesterolemia. Int J Clin Pract 2002; 56: 611-614.

FARNIER M. Statines et prévention cardiovasculaire : les enseignements des essais cliniques. Médecine Thérapeutique Endocrinologie, 2002; 4: 239-246.

FARNIER M. Nouvelles approches médicamenteuses dans le traitement des dyslipidémies. Médecine Thérapeutique Endocrinologie, 2002; 4: 252-259.

FARNIER M, Bortoloni M, Salko T, et al. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003; 91: 238-240.

FARNIER M. Combined therapy with a HMG-CoA Reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Am J Cardiovasc Drugs 2003; 3: 169-178.

FARNIER M. Nouveaux hypolipémiants : prospectives. Thérapie 2003; 58: 97-105.

FARNIER M, SALKO T, ISAACSOHN JL, TROENDLE AJ, DEJAGER S, GONASUN L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin+ fibrate (bezafibrate, fenofibrate or gemfibrozil). Am J Cardiol 2003; 92: 794-797.

ABIFADEL M, VARRET M, RABES JP, ALLARD D, OUGUERRAM K, DEVILLERS M, CRUAUD C, BENJANNET S, WICKHAM L, ERLICH D, DERRE A, VILLEGER L, FARNIER M, BEUCLER I, BRUCKERT E, CHAMBAZ J, CHANU B, LECERF JM, LUC G, MOULIN P, WEISSENBACH J, PRAT A, KREMPF M, JUNIEN C, SEIDAH NG, BOILEAU C. Mutation in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics 2003; 34: 154-156.

FARNIER M. Traitements hypolipémiants : les nouvelles avancées. Nutrition et Facteurs de risque, 2004; n°6: 37-43.

FARNIER M. Le syndrome métabolique : Quelle définition ? Quel risque ? Quelle attitude thérapeutique ? La Lettre du Cardiologue, janvier 2004.

FARNIER M. Faut-il revoir les indications des statines à la lumière des dernières données de la médecine fondée sur les preuves ? EMC – Endocrinologie 2004; n°1: 158-162.

FARNIER M. Essais cliniques et place de l’ézétimibe dans la stratégie thérapeutique des hyperlipidémies. La Lettre du Pharmacologue 2004; 18: 94-100.

FARNIER M, FREEMAN M, MacDONELL G, PEREVOZSKAYA I, DAVIES MJ, MITCHEL YB, GUMBINER B. Efficacy and safety of the co-administration of ezetimibe with fenofibrate in patients with mixed hyperlipidemia. Eur Heart J 2005; 26: 897-905.

ZELLER M, STEG PG, RAVISY J, LAURENT Y, JANIN-MANIFICAT L, L’HUILLER I, BEER JC, OUDOT A, RIOUFOL G, MAKKI H, FARNIER M, ROCHETTE L, VERGES B, COTTIN Y for the Observatoire des Infarctus de Côte-d’Or Survey Working Group. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005; 165: 1192-1198.

FARNIER M, VOLPE M, MASSAAD R, DAVIES MJ, ALLEN C. Effect of co-administering ezetimibe with on-going simvastatin treatement on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005; 102: 327-332.

FARNIER M. Jusqu’où baisser le LDL-cholestérol ? La Lettre du Cardiologue 2005, n° 386, 3-4.

FARNIER M. Prise en charge thérapeutique du patient dyslipidémique. Consensus Cardio, 2005 ; n°9 : 27-29.

FARNIER M. Les dyslipidémies et les facteurs d’inflammation. Cardinale, Collection interdisciplinaire n°5, 2005 : 1-7.

FARNIER M. Qu’est-ce que le HDL-cholestérol ? Cardinale 2005 ; 17 (N° Hors Série) : 6-9.

KASTELEIN J, FARNIER M. New strategies in the treatment of hypercholesterolemia. Timely Top Med Cardiovasc Dis 2005 ; 17 : 9 : E32.

McKENNEY JM, FARNIER M, LO K-W, PEREVOZKAYA I, CARLSON G, DAVIES MJ, MITCHEL YB, GUMBINER B. Safety and efficacy of long-term coadministration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006; 47: 1584-7.

FARNIER M. Diabète de type 2 : Prévention cardiovasculaire par les hypolipémiants. Diabète & facteurs de risque, 2006 ; 4 : 5-11.

FARNIER M. Après FIELD, les fibrates peuvent-ils être utilisés en prévention cardiovasculaire ? MT Cardio 2006 ; 2 : 149-153.

FARNIER M, GARNIER P, YAU C, DEJAGER S, VERPILLEUX MP. Prevalence of low-cholesterol in patients with cardiovascular risk factors : the ECHOS (Etude du Cholesterol HDL en Observationnel) French Survey. Int J Clin Prat 2006; 60: 1166-71.

FARNIER M. Que faut-il faire lorsqu’une statine est mal tolérée chez le patient coronarien ? La lettre du Cardiologue 2006 ; 399 : 17-19.

FARNIER M, ROTH E, GIL-EXTREMERA B, et al. and for the Ezetimibe/Simvastatin + Fenofibrate Study Group. Efficacy and safety of the coadministration of ezetimibe/ simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007; 153: 335e1-335e8.

STEIN EA, MARAIS AD, DUCOBU J, FARNIER M, GAVISH D, HAUNER H, KAPLAN AJ, LE MAULF F, MELEZINKOVA H. A comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia. J Clin Lipidology 2007; 1: 287-299.

FARNIER M. Ezetimibe plus fenofibrate : a new combination therapy for the management of mixed hyperlipidemia? Expert Opin Pharmacol 2007; 8: 1345-1352.

FARNIER M. Les bi- et trithérapies hypolipémiantes : quelles indications, pour quels bénéfices/risques ? Médecine des Maladies Métaboliques 2007 ; 1 : n°3.

STEIN EA, AMERENA J, BALLANTYNE CM, BRICE E, FARNIER M, GUTHRIE EM, HARATS D, MA PTS, LE MAULF F, MELEZINKOVA H, GOLD A, SAGER P. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am J Cardiol 2007 ; 100 : 1387-1396.

FARNIER M, BONNET F, BRUCKERT E, FERRIERES J, PAILLARD F. Quand proposer une association d’hypolipémiants chez un patient non à l’objectif thérapeutique sous monothérapie ? Recommandations de la NSFA. Archives des Maladies du Cœur et des Vaisseaux 2007 ; 100 : 569-581.

FARNIER M. Setting a new standard in achieving superior efficacy : ezetimibe + simvastatin. Fundam Clin Pharmacol 2007; 21 (Suppl. 2) : 27-8.

ZELLER M, MASSON D, FARNIER M, et al. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol 2007; 50 : 1948-55.

FARNIER M. Dyslipidemia and abdominal obesity : mechanisms and characteristics (Part. I). Arch Mal Cœur Vaiss 2007; 100 : 979-984.

FARNIER M. Dyslipidemia and abdominal obesity : therapeutic approaches (Part. II). Arch Mal Cœur Vaiss 2007; 100 : 985-987, 990-991.

TRIBBLE DL, FARNIER M, MacDONELL G et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in co-administration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metab Clin Experim 2008; 57: 796-801.

 

FARNIER M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vasc Health Risk Manag 2008; 4: 991-1000.

LABLANCHE JM, DANCHIN N, FARNIER M, TEDGUI A, VICAUT E, ALONSO J, CREAN P, LEONE A, MORAIS J, SANTINI M, LICOUR M, FARAH M, TARDIF JC. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: the CENTAURUS trial design. Arch Cardiovasc Dis 2008; 101: 399-406.

STEG PG, VERDIER J-C, CARRE F, DARNE B, DUCARDONNET A, JULLIEN G, FARNIER M, GIRAL P, HAÏAT R, on behalf of the TWICE Investigators. A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE). Arch Cardiovasc Dis 2008; 101: 723-735.

FARNIER M. La modulation du HDL-cholestérol a-t-elle un avenir ? La Lettre du Cardiologue 2008 ; n° 418 : 24-27.

FARNIER M, PEREVOZSKAYA I, TAGGART WV, KUSH D, MITCHEL YB. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J Lipid Res 2008; 49: 2641-2647.

CORSINI A, WINDLER E, FARNIER   M. Colesevelam hydrochloride: usefulness of a specifically-engineered bile acid sequestrant (BAS) for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil 2009; 16 (1): 1-9.

FARNIER M. Quel bilan lipidique et comment l’interpréter chez le patient ayant une maladie coronaire ? Presse Med 2009 ; 38 : 958-963.

FARNIER M, AVERNA M, MISSAULT L, VAVERKOVA H, VIIGIMAA M, MASSAAD R, VANDORMAEL K, JOHNSON-LEVONAS A.O, BRUDI P. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – The INCROSS Study. Int J Clin Pract 2009; 63: 547-559.

FARNIER M. Pharmacotherapy of mixed hyperlipidemia with ezetimibe-fenofibrate combination therapy. Clinical Medicine: Therapeutics 2009; 1: 1703-1713.

VAVERKOVA H, FARNIER M, AVERNA M, MISSAULT L, VIIGIMAA M, DONG Q, SHAH A, JOHNSON-LEVONAS AO, BRUDI P. Lipid-Altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled with prior statin monotherapy. Cardiovasc Ther 2010; online.

FARNIER M, DUCOBU J, BRYNIARSKI L. Efficacy and safety of adding fenofibrate 160 mg in high risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg. Am J Cardiol 2010; 106: 787-792.

VIIGIMAA M, VAVERKOVA H, FARNIER M, AVERNA M, MISSAULT L, HANSON ME, DONG Q, SHAH A, BRUDI P. Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids Health Dis 2010; 9: 127.

MARDUEL M, CARRIE A, SASSOLAS A, DEVILLERS M, CARREAU V, DI FILIPPO M; ERLICH D, ABIFADEL M, MARQUES-PINHEIRO A, MUNNICH A, JUNIEN C, FRENCH ADH Research Network, BOILEAU C, VARRET M, RABES JP, FARNIER M, LUC G, LECERF JM, BRUCKERT E, BONNEFONT-ROUSSELOT D, GIRAL P, KALOPISSIS A, GIRARDET JP, POLAK M, CHANU B, MOULIN P, PERROT L, KREMPF M, ZAIR Y, BONNET J, FERRIERES J, FERRIERES D, BONGARD V, COURNOT M, REZNICK Y, SCHLIENGER JL, FREDENRICH A, DURLACH V. Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum Mutat 2010; 31: E1811-24.

FARNIER M. Extended-release niacin and laropiprant in the management of dyslipidemias. Clin Lipidol 2010; 5: 783-91.

LUC G, GIRARDET J-P, BRUCKERT E, RIEU D, FARNIER M, DARMAUN D. Recommandations pour la prise en charge des hypercholestérolémies chez l’enfant. STV 2010 ; 22 : 465-77.

FARNIER M. Safety review of combination drugs for hyperlipidemia. Exp Opin Drugs Saf 2011; 10: 363-71.

GIRARDET J-P, LUC G, RIEU D, BRUCKERT E, DARMAUN D, FARNIER M. Prise en charge des hypercholestérolémies de l’enfant : recommandations du comité de nutrition de la société française de pédiatrie et de la nouvelle société française d’athérosclérose. Arch Ped 2011; 18 : 217-29.

FARNIER M, Steinmetz A, Retterstøl K, Császár A. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. Clin Ther 2011; 33 : 1-12.

LEITER LA, BETTERIDGE DJ, FARNIER M, GUYTON JR, LIN J, SHAH A, JOHNSON-LEVONAS AO, BRUDI P. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin versus statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab. 2011; 13: 615-28.

GUYTON JR, BETTERIDGE DJ, FARNIER M, LEITER LA, LIN J, SHAH A, JOHNSON-LEVONAS AO, BRUDI P. Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. Diab Vasc Dis Res 2011; 8:160-72.

FARNIER M, TAGGART W, DONG Q, LIN J , SHAH A, BRUDI P. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of LDL and non-HDL cholesterol with apolipoprotein B in mixed dyslipidemic patients. J Clin Lipidol 2011; 5: 179-87.

VAVERKOVA H, FARNIER M, AVERNA M, MISSAULT L, VIIGIMAA M, DONG Q, SHAH A, JOHNSON-LEVONAS A, BRUDI P. Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients at high risk of coronary disease. Clin Biochem 2011; 44: 627-34.

FARNIER M. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Am J Cardiovasc Drugs 2011; 11: 145-52.

AVERNA M, MISSAULT L, VAVERKOVA H, FARNIER M, VIIGIMAA M, DONG Q, SHAH A, JOHNSON-LEVONAS AO, TAGGART W, BRUDI P. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diab Vasc Dis Res 2011; 8: 262-70.

BRUCKERT E, FERRIERES J, FARNIER M. HDL-cholestérol et approche thérapeutique. Arch Cardiovasc Dis Suppl 2011 ; 3 : 215-21

FARNIER M. Et le HDL-cholestérol ? [What about HDL-cholesterol ?] Revue du Praticien ; 2011 : 61(8) : 1117-20.

FARNIER M, DONG Q, SHAH A, JOHNSON-LEVONAS AO, BRUDI P. Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. Lipids Health Dis 2011; 10: 212.

FARNIER M, DUCOBU J, BRYNIARSKI L. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy. Curr Med Res Opin 2011; 27: 2165-73.